PD48: Bladder Cancer: Non-invasive III
304A
Poster and Podium Sessions
Oncology: Bladder/Upper-Tract/Urethral
Information
Continuing Medical Education
CME
Sunday, May 5
PD48-01: Efficacy of Nadofaragene Firadenovec-vncg for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Final Results From a Phase 3 Trial
Sunday, May 5, 2024 1:00 PM to 1:10 PM
304A
PD48-02: First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations
Sunday, May 5, 2024 1:10 PM to 1:20 PM
304A
PD48-03: Detecting residual tumor with cell-free urinary tumor DNA in high-risk non-muscle invasive bladder cancer patients
Sunday, May 5, 2024 1:20 PM to 1:30 PM
304A
PD48-04: Does enhanced audit and feedback with education improve quality indicator (QI) achievement and reduce early recurrence rates in TURBT surgery for NMIBC? Results from the RESECT cluster randomised trial.
Sunday, May 5, 2024 1:30 PM to 1:40 PM
304A
PD48-05: Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis
Sunday, May 5, 2024 1:40 PM to 1:50 PM
304A
PD48-06: Urine cellular DNA methylation and mutation test for detecting urothelial carcinoma
Sunday, May 5, 2024 1:50 PM to 2:00 PM
304A
PD48-07: Pivotal Study Evaluating Performance of Bladder EpiCheck, an FDA cleared test, in Non-Muscle Invasive Bladder Cancer
Sunday, May 5, 2024 2:00 PM to 2:10 PM
304A
PD48-08: Comparative analysis of methylation biomarkers in tumor and urinary tumor DNA in high-risk non-muscle invasive bladder cancer patients
Sunday, May 5, 2024 2:10 PM to 2:20 PM
304A
PD48-09: A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Systemic Therapy Versus Standard of Care Intravesical Treatment (BCG) in Non-Muscle Invasive Bladder Cancer Patients
Sunday, May 5, 2024 2:20 PM to 2:30 PM
304A
PD48-10: Comutations in FGFR3-Altered NMIBC Influence Recurrence/Progression
Sunday, May 5, 2024 2:30 PM to 2:40 PM
304A
PD48-11: En bloc vs. conventional transurethral resection of bladder tumor: Two-year oncological follow-up of a single-center prospective, randomized, controlled, non-inferiority trial
Sunday, May 5, 2024 2:40 PM to 2:50 PM
304A
PD48-12: Patient-Reported Toxicity During Intravesical Therapy for Non-Muscle Invasive Bladder Cancer
Sunday, May 5, 2024 2:50 PM to 3:00 PM
304A
